Beijing Beilu Pharmaceutical (300016) — Net Asset Quality Index
Beijing Beilu Pharmaceutical (300016) has a Net Asset Quality Index of 73.5% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.22 Billion minus total liabilities of CN¥852.80 Million yields net assets of CN¥2.37 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 300016 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing Beilu Pharmaceutical Net Asset Quality Index Over Time (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Net Asset Quality Index has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the index stands at 73.5%, representing net assets of CN¥2.37 Billion against total assets of CN¥3.22 Billion CNY. Explore 300016 cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Beijing Beilu Pharmaceutical (2005–2024)
The table below presents the year-by-year Net Asset Quality Index for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Beijing Beilu Pharmaceutical market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 61.4% | CN¥1.83 Billion | CN¥2.98 Billion | CN¥1.15 Billion | ▼ -1.9 pp |
| 2023 | 63.4% | CN¥1.79 Billion | CN¥2.82 Billion | CN¥1.03 Billion | ▼ -5.0 pp |
| 2022 | 68.3% | CN¥1.92 Billion | CN¥2.82 Billion | CN¥892.27 Million | ▼ -3.5 pp |
| 2021 | 71.8% | CN¥2.08 Billion | CN¥2.90 Billion | CN¥818.22 Million | ▲ +5.4 pp |
| 2020 | 66.4% | CN¥1.89 Billion | CN¥2.85 Billion | CN¥955.50 Million | ▼ -22.9 pp |
| 2019 | 89.3% | CN¥1.45 Billion | CN¥1.62 Billion | CN¥173.31 Million | ▼ -4.2 pp |
| 2018 | 93.6% | CN¥1.21 Billion | CN¥1.29 Billion | CN¥82.93 Million | ▼ -0.2 pp |
| 2017 | 93.7% | CN¥1.07 Billion | CN¥1.14 Billion | CN¥71.65 Million | ▼ -0.6 pp |
| 2016 | 94.3% | CN¥901.69 Million | CN¥956.09 Million | CN¥54.40 Million | ▲ +5.5 pp |
| 2015 | 88.8% | CN¥932.63 Million | CN¥1.05 Billion | CN¥117.39 Million | ▲ +15.4 pp |
| 2014 | 73.5% | CN¥666.33 Million | CN¥907.00 Million | CN¥240.67 Million | ▼ -16.7 pp |
| 2013 | 90.1% | CN¥559.38 Million | CN¥620.54 Million | CN¥61.16 Million | ▲ +0.4 pp |
| 2012 | 89.8% | CN¥523.96 Million | CN¥583.60 Million | CN¥59.64 Million | ▼ -3.9 pp |
| 2011 | 93.7% | CN¥491.47 Million | CN¥524.66 Million | CN¥33.19 Million | ▼ -4.7 pp |
| 2010 | 98.4% | CN¥467.62 Million | CN¥475.11 Million | CN¥7.49 Million | ▲ +2.3 pp |
| 2009 | 96.1% | CN¥433.71 Million | CN¥451.31 Million | CN¥17.60 Million | ▲ +12.7 pp |
| 2008 | 83.4% | CN¥133.23 Million | CN¥159.75 Million | CN¥26.52 Million | ▲ +19.6 pp |
| 2007 | 63.8% | CN¥90.33 Million | CN¥141.69 Million | CN¥51.36 Million | ▲ +6.8 pp |
| 2006 | 57.0% | CN¥71.59 Million | CN¥125.69 Million | CN¥54.10 Million | ▼ -3.3 pp |
| 2005 | 60.2% | CN¥64.71 Million | CN¥107.46 Million | CN¥42.75 Million | — |